Patent ID: 9683038
Date: 2017-06-20
CPC Classifications: A61K,A61P,C07K

Claim:
1. A method of reducing risk of experiencing a cardiovascular (CV) event or a cerebrovascular event in a stable patient who has had a prior myocardial infarction (MI), comprising subcutaneously administering 50 mg to 300 mg of an IL-1β binding antibody or functional fragment thereof to the patient every three months, wherein said patient has a hsCRP level of ≧2 mg/L before administration of said antibody or functional fragment thereof, and wherein said IL-1β binding antibody or functional fragment thereof comprises: a) the three complementarity determining regions (CDRs) set forth as SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and the three CDRs set forth as SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8; or b) a V